Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-24 @ 9:14 PM
NCT ID:
NCT00976404
Eligibility Criteria:
Inclusion Criteria:
* HIV-1 infection
* At least 3 years of ART without interruption (less than one month cumulative)
* ART regimen unchanged in the 3 months prior to screening
* One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at least 2 HIV plasma viral load (RNA) documented per year thereafter
* HIV plasma viral load (RNA) ≤ 500 copies/mL at least 3 years prior to entry, and HIV plasma viral load \< 500 copies/mL for \>90% of the measures thereafter
* HIV plasma viral load (RNA) below the limit of detection for all values within the past year (one virologic blip allowed)
* HIV plasma viral load below the limit of detection within 60 days of entry
* CD4+ count ≥ 350 cells/mm3 within 60 days of entry
* Proviral DNA ≥10 and ≤1000 copies/106 PBMCs within 75 days of entry
* Adeno5 neutralizing antibody titers of 250 or less within 75 days of entry
* Hemoglobin ≥ 10 g/dL within 60 days of entry
* Platelets ≥ 100,000 per microliter within 60 days of entry
* Hepatic transaminases (ALT and AST) ≤ 2.5 x ULN within 60 days of entry
* Creatinine clearance \> 50 mL/min by the Cockcroft-Gault equation within 60 days of entry
Exclusion Criteria:
* Sexually active men and women who will not practice at least one form of barrier birth control (male partner using condoms, female partner using condoms, other barrier contraception, etc)
* Pregnancy
* Inability or unwillingness to provide informed consent
* HBsAg positive
* HCV antibody positive or HCV RNA detectable
* Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such as intensification or toxicity switches is allowed.
* Immunologic therapeutic intervention (e.g. IL-2) within the past year
* Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted
* Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and cutaneous KS not requiring systemic therapy)
* Co-morbid condition with an expected survival of less than 12 months
* History of hypersensitivity to vaccination
* History of autoimmune disease, such as systemic lupus erythematosis (SLE) or Hashimoto's thyroiditis
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT00976404
Study Brief:
Protocol Section:
NCT00976404